Chemical biology of steroid and nuclear hormone receptors

Current Opinion in Chemical Biology

Volumn 11, Issue 1, 2007, Pages 99-110

  Biggins, John B ^a   Koh, John T ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; ESTRADIOL; GENOMIC DNA; HORMONE RECEPTOR; LIGAND; PROGESTERONE; STEROID; TESTOSTERONE; TRANSCRIPTION FACTOR; VITAMIN D;

BREAST CANCER; DRUG DESIGN; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION; GENETIC ENGINEERING; GENOME; HORMONE ACTION; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN DEGRADATION; REVIEW; RICKETS; TRANSGENE;

ANIMALS; DNA; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT PROTEINS; STEROIDS; TRANSCRIPTION FACTORS; TRANSGENES;

EID: 33846813770     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2006.10.042     Document Type: Review

References (71)

1. Laudet V., and Gronemeyer H. The Nuclear Receptor Facts Book (2002), Acedemic Press, London
2. Ribeiro R.C., Kushner P.J., and Baxter J.D. The nuclear hormone receptor gene superfamily. Annu Rev Med 46 (1995) 443-453
3. Koh J.T. Engineering selectivity and discrimination into ligand-receptor interfaces. Chem Biol 9 (2002) 17-23
4. Koh J.T., and Biggins J.B. Ligand-receptor engineering and its application towards the complementation of genetic disease and target identification. Curr Top Med Chem 5 (2005) 413-420. A concise review detailing the concepts of ligand orthogonality and the molecular complementation of hormone receptors.
5. Doyle D.F., Braasch D.A., Jackson L.K., Weiss H.E., Boehm M.F., Mangelsdorf D.J., and Corey D.R. Engineering orthogonal ligand-receptor pairs from 'near drugs'. J Am Chem Soc 123 (2001) 11367-11371
6. Peet D.J., Doyle D.F., Corey D.R., and Mangelsdorf D.J. Engineering novel specificities for ligand-activated transcription in the nuclear hormone receptor RXR. Chem Biol 5 (1998) 13-21
7. Koh J.T., Putnam M., Tomic-Canic M., and McDaniel C.M. Selective regulation of gene expression using rationally-modified retinoic acid receptors. J Am Chem Soc 121 (1999) 1984-1985
8. Shi Y., and Koh J.T. Selective regulation of gene expression by an orthogonal estrogen receptor-ligand pair created by polar-group exchange. Chem Biol 8 (2001) 501-510
9. Shi Y., and Koh J.T. Functionally orthogonal ligand-receptor pairs for the selective regulation of gene expression generated by manipulation of charged residues at the ligand-receptor interface of ERα and ERβ. J Am Chem Soc 124 (2002) 6921-6928
10. Tedesco R., Thomas J.A., Katzenellenbogen B.S., and Katzenellenbogen J.A. The estrogen receptor: a structure-based approach to the design of new specific hormone-receptor combinations. Chem Biol 8 (2001) 277-287
11. Hassan A.Q., and Koh J.T. A functionally orthogonal ligand-receptor pair created by targeting the allosteric mechanism of the thyroid hormone receptor. J Am Chem Soc 128 (2006) 8868-8874. By mimicking known mutations found in resistance to hormone diseases, a crucial amino acid residue within TRβ is mutated that fosters an allosteric interaction necessary for coactivator recruitment. The resulting loss of function is subsequently rescued with a designed mutant-selective analog displaying high potency and orthogonal specificity, as displayed with genetic assays across multiple response elements.
12. No D., Yao T.P., and Evans R.M. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 93 (1996) 3346-3351
13. Fussenegger M. The impact of mammalian gene regulation concepts on functional genomic research, metabolic engineering, and advanced gene therapies. Biotechnol Prog 17 (2001) 1-51
14. Weber W., and Fussenegger M. Pharmacologic transgene control systems for gene therapy. J Gene Med 8 (2006) 535-556
15. Lafont R., and Dinan L. Practical uses for ecdysteroids in mammals including humans: an update. J Insect Sci 3 (2003) 7
16. Dhadialla T.S., Carlson G.R., and Le D.P. New insecticides with ecdysteroidal and juvenile hormone activity. Annu Rev Entomol 43 (1998) 545-569
17. Whelan J., and Miller N. Generation of estrogen receptor mutants with altered ligand specificity for use in establishing a regulatable gene expression system. J Steroid Biochem Mol Biol 58 (1996) 3-12
18. Chockalingam K., Chen Z., Katzenellenbogen J.A., and Zhao H. Directed evolution of specific receptor-ligand pairs for use in the creation of gene switches. Proc Natl Acad Sci USA 102 (2005) 5691-5696
19. Schwimmer L.J., Rohatgi P., Azizi B., Seley K.L., and Doyle D.F. Creation and discovery of ligand-receptor pairs for transcriptional control with small molecules. Proc Natl Acad Sci USA 101 (2004) 14707-14712
20. Gallinari P., Lahm A., Koch U., Paolini C., Nardi M.C., Roscilli G., Kinzel O., Fattori D., Muraglia E., Toniatti C., et al. A functionally orthogonal estrogen receptor-based transcription switch specifically induced by a nonsteroid synthetic ligand. Chem Biol 12 (2005) 883-893
21. Roscilli G., Rinaudo C.D., Cimino M., Sporeno E., Lamartina S., Ciliberto G., and Toniatti C. Long-term and tight control of gene expression in mouse skeletal muscle by a new hybrid human transcription factor. Mol Ther 6 (2002) 653-663
22. Chen Z., and Zhao H. Rapid creation of a novel protein function by in vitro coevolution. J Mol Biol 348 (2005) 1273-1282. The authors used directed evolution to engineer proteins of distant ligand recognition function by step-wise selection for recognition of ligands that gradually increase in target-like properties. By coupling evolved protein activity (in the form of transgene activation of a selection marker) with positive ligand-receptor interactions, an estrogen receptor was evolved towards responsiveness with testosterone; this receptor was further evolved towards progesterone activity, which, in turn, was additionally evolved towards cortisone responsiveness.
23. Semple R.K., Chatterjee V.K., and O'Rahilly S. PPARγ and human metabolic disease. J Clin Invest 116 (2006) 581-589
24. Hashimoto A., Shi Y., Drake K., and Koh J.T. Design and synthesis of complementing ligands for mutant thyroid hormone receptor TRβ(R320H): a tailor-made approach toward the treatment of resistance to thyroid hormone. Bioorg Med Chem 13 (2005) 3627-3639
25. Shi Y., Ye H., Link K.H., Putnam M.C., Hubner I., Dowdell S., and Koh J.T. Mutant-selective thyromimetics for the chemical rescue of thyroid hormone receptor mutants associated with resistance to thyroid hormone. Biochemistry 44 (2005) 4612-4626
26. Swann S.L., Bergh J., Farach-Carson M.C., Ocasio C.A., and Koh J.T. Structure-based design of selective agonists for a rickets-associated mutant of the vitamin D receptor. J Am Chem Soc 124 (2002) 13795-13805
27. Swann S.L., Bergh J.J., Farach-Carson M.C., and Koh J.T. Rational design of vitamin D-3 analogues which selectively restore activity to a vitamin D receptor mutant associated with rickets. Org Lett 4 (2002) 3863-3866
28. Ye H.F., O'Reilly K.E., and Koh J.T. A subtype-selective thyromimetic designed to bind a mutant thyroid hormone receptor implicated in resistance to thyroid hormone. J Am Chem Soc 123 (2001) 1521-1522
29. Mayer G., and Heckel A. Biologically active molecules with a 'light switch'. Angew Chem Int Ed Engl 45 (2006) 4900-4921
30. Cruz F.G., Koh J.T., and Link K.H. Light-activated gene expression. J Am Chem Soc 122 (2000) 8777-8778
31. Shi Y., and Koh J.T. Light-activated transcription and repression by using photocaged SERMs. ChemBioChem 5 (2004) 788-796. The authors exploited the promoter-specific ability of the selective estrogen receptor modulator, 4-hydroxytamoxifen, to act as both an agonist and antagonist by caging a crucial residue with a photo-labile nitroverityl group towards enforcing light-activated spatiotemporal control over transgene expression and repression.
32. Link K.H., Cruz F.G., Ye H.F., O'Reilly K.E., Dowdell S., and Koh J.T. Photo-caged agonists of the nuclear receptors RARγ and TRβ provide unique time-dependent gene expression profiles for light-activated gene patterning. Bioorg Med Chem 12 (2004) 5949-5959. Differential intracellular expression profiles, as patterned by light-activated gene expression, are displayed between receptors RARγ and TRβ, both partnered with the identical DR4 hormone response element.
33. Lin W., Albanese C., Pestell R.G., and Lawrence D.S. Spatially discrete, light-driven protein expression. Chem Biol 9 (2002) 1347-1353
34. Link K.H., Shi Y., and Koh J.T. Light-activated recombination. J Am Chem Soc 127 (2005) 13088-13089
35. Cambridge S.B., Geissler D., Keller S., and Curten B. A caged doxycycline analogue for photoactivated gene expression. Angew Chem Int Ed Engl 45 (2006) 2229-2231
36. Sakamoto K.M. Chimeric molecules to target proteins for ubiquitination and degradation. Methods Enzymol 399 (2005) 833-847
37. Sakamoto K.M., Kim K.B., Verma R., Ransick A., Stein B., Crews C.M., and Deshaies R.J. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteomics 2 (2003) 1350-1358
38. Buskirk A.R., Ong Y.C., Gartner Z.J., and Liu D.R. Directed evolution of ligand dependence: small-molecule-activated protein splicing. Proc Natl Acad Sci USA 101 (2004) 10505-10510. The authors expand upon established in vivo techniques for post-translational peptide recombination by evolving an apo-protein into a protein whose recombination and subsequent activity is hormone gated by an internal estrogen receptor ligand-binding domain.
39. Hahn M.E., and Muir T.W. Manipulating proteins with chemistry: a cross-section of chemical biology. Trends Biochem Sci 30 (2005) 26-34
40. Yuen C.M., Rodda S.J., Vokes S.A., McMahon A.P., and Liu D.R. Control of transcription factor activity and osteoblast differentiation in Mammalian cells using an evolved small-molecule-dependent intein. J Am Chem Soc 128 (2006) 8939-8946
41. Awais M., Sato M., Lee X., and Umezawa Y. A fluorescent indicator to visualize activities of the androgen receptor ligands in single living cells. Angew Chem Int Ed Engl 45 (2006) 2707-2712. The androgen receptor ligand-binding domain is fused between two fluorophores, whose FRET-based interaction provides a rapid visual assay of efficacious ligand binding and/or receptor antagonism.
42. Norman A.W., Mizwicki M.T., and Norman D.P.G. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3 (2004) 27-41
43. 3 indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-s-cis- nor 6-s-trans-locked analogs are preferred for genomic biological responses. Mol Endocrinol 11 (1997) 1518-1531
44. 3 signaling. Proc Natl Acad Sci USA 101 (2004) 12876-12881. A putative novel ligand-binding domain (the 'A-pocket') of the vitamin D receptor is modeled from known data, by coupling two flexible vitamin D metabolite ligand structures with differential receptor function.
45. Billas I.M., Iwema T., Garnier J.M., Mitschler A., Rochel N., and Moras D. Structural adaptability in the ligand-binding pocket of the ecdysone hormone receptor. Nature 426 (2003) 91-96. Two structurally unrelated ligand agonists (the ecdysteroid ponansterone A and the bisacylhydrazine ligand BYI06830) are shown to induce altered conformations within the ecdysone receptor ligand-binding domain, suggesting the adaptability of nuclear receptors to specific ligand partners.
46. Schlattner U., Vafopoulou X., Steel C.G., Hormann R.E., and Lezzi M. Non-genomic ecdysone effects and the invertebrate nuclear steroid hormone receptor EcR-new role for an 'old' receptor?. Mol Cell Endocrinol 247 (2006) 64-72
47. Schapira M., Abagyan R., and Totrov M. Nuclear hormone receptor targeted virtual screening. J Med Chem 46 (2003) 3045-3059
48. Losel R.M., Falkenstein E., Feuring M., Schultz A., Tillmann H.C., Rossol-Haseroth K., and Wehling M. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83 (2003) 965-1016
49. Bergh J.J., Lin H.Y., Lansing L., Mohamed S.N., Davis F.B., Mousa S., and Davis P.J. Integrin αVβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146 (2005) 2864-2871
50. Thomas P., Pang Y., Filardo E.J., and Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 (2005) 624-632
51. Tobias S.C., Qiu J., Kelly M.J., and Scanlan T.S. synthesis and biological evaluation of SERMs with potent nongenomic estrogenic activity. ChemMedChem 1 (2006) 565-571. A unique stereospecific raloxifene-tamoxifen hybrid molecule, ST-X, is shown to induce nongenomic GPR30 estrogenic signaling without activating nuclear estrogen-based transcription.
52. Scanlan T.S., Suchland K.L., Hart M.E., Chiellini G., Huang Y., Kruzich P.J., Frascarelli S., Crossley D.A., Bunzow J.R., Ronca-Testoni S., et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 10 (2004) 638-642
53. 2A adenosine receptor and its agonists. Chem Biol 12 (2005) 237-247
54. Edwards D.P. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67 (2005) 335-376
55. Kampa M., and Castanas E. Membrane steroid receptor signaling in normal and neoplastic cells. Mol Cell Endocrinol 246 (2006) 76-82
56. Unni E., Sun S.H., Nan B.C., McPhaul M.J., Cheskis B., Mancini M.A., and Marcelli M. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64 (2004) 7156-7168
57. Simoncini T., and Genazzani A.R. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148 (2003) 281-292
58. Li L., Haynes M.P., and Bender J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 100 (2003) 4807-4812
59. Glaros S., Atanaskova N., Zhao C., Skafar D.F., and Reddy K.B. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. Mol Endocrinol 20 (2006) 996-1008
60. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., and Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 (2004) 926-935
61. Vasudevan N., Kow L.M., and Pfaff D.W. Early membrane estrogenic effects required for full expression of slower genomic actions in a nerve cell line. Proc Natl Acad Sci USA 98 (2001) 12267-12271
62. Harrington W.R., Kim S.H., Funk C.C., Madak-Erdogan Z., Schiff R., Katzenellenbogen J.A., and Katzenellenbogen B.S. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol 20 (2006) 491-502. Non-nuclear signaling pathways are exclusively activated by an estrogenic dendrimer, whereby multiple estrogen molecules are linked to a poly(amido)amine core, designed to localize and function solely at the outer membrane.
63. Acconcia F., Ascenzi P., Bocedi A., Spisni E., Tomasi V., Trentalance A., Visca P., and Marino M. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17β-estradiol. Mol Biol Cell 16 (2005) 231-237. The authors demonstrate that the palmitoylation of the single cysteine-447 residue, conserved among the sex hormone nuclear receptors, is necessary for proper membrane templating and subsequent nongenomic signaling of ERα.
64. Resh M.D. Membrane targeting of lipid modified signal transduction proteins. Subcell Biochem 37 (2004) 217-232
65. Wong C.W., McNally C., Nickbarg E., Komm B.S., and Cheskis B.J. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99 (2002) 14783-14788
66. Barletta F., Wong C.W., McNally C., Komm B.S., Katzenellenbogen B., and Cheskis B.J. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol 18 (2004) 1096-1108. The authors characterize the scaffolding protein MNAR that facilitates the estrogen-dependent ER activation of oncogenic signaling pathways instigated by the Src kinase pathway.
67. Haas D., White S.N., Lutz L.B., Rasar M., and Hammes S.R. The modulator of nongenomic actions of the estrogen receptor (MNAR) regulates transcription-independent androgen receptor-mediated signaling: evidence that MNAR participates in G protein-regulated meiosis in Xenopus laevis oocytes. Mol Endocrinol 19 (2005) 2035-2046
68. Rajhans R., and Vadlamudi R.K. Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR. Clin Exp Metastasis 23 (2006) 1-7
69. Bologa C.G., Revankar C.M., Young S.M., Edwards B.S., Arterburn J.B., Kiselyov A.S., Parker M.A., Tkachenko S.E., Savachuck N.P., Sklar L.A., et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2 (2006) 207-212
70. Ocasio C.A., and Scanlan T.S. Design and characterization of a thyroid hormone receptor α(TRα)-specific agonist. ACS Chem Biol 1 (2006) 585-593
71. Paulmurugan R., and Gambhir S.S. An intermolecular folding sensor for imaging estrogen receptorligand interactions. Proc Natl Acad Sci USA 103 (2006) 15883-15888